Impact of EGFR mutations on treatment of non-small cell lung cancer Bruce E. JohnsonDavid JackmanPasi A. Jänne OriginalPaper 09 November 2006 Pages: 5 - 9
Defining clinically relevant molecular subsets of lung cancer William Pao OriginalPaper 09 November 2006 Pages: 11 - 15
Molecular classification of tumors with special reference to EGFR mutation in lung cancer Yasushi Yatabe OriginalPaper 09 November 2006 Pages: 17 - 23
The impact and role of EGFR gene mutation on non-small cell lung cancer Shinichi ToyookaJunichi SohHiroshi Date OriginalPaper 09 November 2006 Pages: 25 - 31
Clinical development of EGFR-tyrosine kinase inhibitors in Japan Kazuhiko Nakagawa OriginalPaper 09 November 2006 Pages: 33 - 37
EGFR mutation in various tissues Kazuto NishioTokuzo AraoHideyuki Yokote OriginalPaper 09 November 2006 Pages: 39 - 41
A randomized phase III trial of adjuvant treatment for resected non-small cell lung cancer in Japan Yukito Ichinose OriginalPaper 09 November 2006 Pages: 43 - 48
Improving upon the promise of targeted therapy of human malignancy: chronic myeloid leukemia as a paradigm Neil P. Shah OriginalPaper 09 November 2006 Pages: 49 - 53
Development of NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor Shinya KimuraTomoko NiwaTaira Maekawa OriginalPaper 09 November 2006 Pages: 55 - 61
An endothelium-derived angiogenesis inhibitor vasohibin and its significance in tumor angiogenesis Yasufumi Sato OriginalPaper 09 November 2006 Pages: 69 - 72